Trial Profile

Assessment of the Diagnostic Value of 64Cu-SAR-BBN PET Imaging for Men With Negative PSMA PET in Prostate Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs 64Cu SAR bombesin-Clarity Pharmaceuticals (Primary)
Indications Prostate cancer
Focus Diagnostic use
Acronyms BOP

Most Recent Events

24 Jul 2023 Status changed from recruiting to active, no longer recruiting, according to a Clarity Pharmaceuticals media release.
07 Jun 2023 According to a Clarity Pharmaceuticals media release, company announced the completion of recruitment 30 participants with prostate cancer.
15 Sep 2022 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com